I don't know, something is fishy with that report and TARO is going to face a slew of lawsuits shortly. Sales dropping by 30% and all of that due to "inventory adjustments" at their wholesalers? Nope, something more fundamental is happening. I would not be surprised that this is the reaction of various bodies to TARO trying to evade Israeli taxation by moving out a little while back, or an organized "boycott" of one kind or another by wholesalers or end users. Something is quite fishy when a generic drug supplier that does not depend on a single drug for its sales suffers a 30% QOQ sales decline. I will wait for few additional shoes to drop...